Your SlideShare is downloading. ×
Toxicity of aminoglycoside antibiotics
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Toxicity of aminoglycoside antibiotics

3,670
views

Published on

by ajith covas mannuthy

by ajith covas mannuthy

Published in: Health & Medicine, Technology

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
3,670
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
74
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. TOXICITY OF AMINOGLYCOSIDE ANTIBIOTICS
  • 2. INTRODUCTION• Group of natural and semisynthetic antibiotics.• Amino sugar + aminocyclitol via glycoside bond.• Streptomycin – 1st discovered – 1944 – Waksman & co-workers from Streptomyces griseus ( actinobacterium )• Amikacin – 1st semi synthetic – from Kanamycin• Bactericidal drug – Inhibit protein synthesis – Formation of aberrant proteins – streptomycin (bind with 30S subunit) – others (bind with 50S subunit) – Bacteria more permeable – leakage – cell death
  • 3. • Excellent water solubility – Poor lipid soluble.• Nephrotoxicity – due to increased no: of amino groups Eg :- Neomycin – 6 amino group – more toxic Streptomycin – 3 amino group – less toxic• They are not absorbed from the gut. So I/m or I/v• Uses : Local & Systemic infection – Mainly Gram –ve• In Vet practice, Neomycin – toxic – so topical only Gentamicin – Broad spectrum antibiotic
  • 4. I. NEPHROTOXICITY• Excessive accumulation in PCT cells ( 40 – 50 times than in blood )• Basic polycation, attract to membrane phospholipids• High Phosphatidyl inositol content – PCT & Cochlea• Pinocytosis – sequestrate in lysosomes –interact with organelles - cell death – cell necrosis• Inhibit phospholipidases, ATPases - reduced PG synthesis – direct effect on GFR.
  • 5. • Toxicity reversible initially- renewable PCT cells• Manifestations : Enzymes of brush border in urine, proteinuria, casts, low GFR etc..• Reduced antibiotic clearance – lead to ototoxicity• Later stages - polyuria – loss of response to ADH• Neomycin – 6 amino group – more toxic DihydroStreptomycin – 3 amino group – less toxic
  • 6. II. OTOTOXICITY• Both Vestibular & auditory dysfunction• Accumulate in perilymph & endolymph• Ototoxicity – irreversible – Non renewable cells• Cochlear damage – Hearing loss (high frequency sound first) – loss of hair cells in Organ of Corti• Vestibular damage – Affect balance of body – Nystagmus, incoordination, vertigo, head tilt, ataxia, loss of righting reflex etc...
  • 7. • Vestibulotoxicity – Streptomycin > Gentamicin• Ototoxicity – Neomycin > Kanamycin & Amikacin• Cats are more susceptible than dogs.• Renal dysfunction increase ototoxicity
  • 8. III NEUROMUSCULAR BLOCKAGE• Interfere Acetyl Choline release from motor nerve ending – antagonism of Calcium ( exocytosis )• Decrease sensitivity of post synaptic membrane• Toxicity only when administer along with neuromuscular blocking agent & general anesthetic• Muscular weakness, apnea, respiratory arrest• Neomycin & Streptomycin high side effect
  • 9. IV OTHER EFFECTS• Less allergic reactions• Peripheral neuritis & optic nerve damage• Intestinal malabsorption syndrome• Diarrhea, Flattening of intestinal villi etc…
  • 10. DRUG INTERACTIONS• Loop diuretics or Osmotic diuretics => Enhanced nephrotoxicity & ototoxicity• Inhalant anesthetics or neuromuscular blocking agents => respiratory paralysis• Halothane => Cardiovascular depression• Cephalosporin => additive nephrotoxicity• Carbenicillin or Ticarcillin => inactivate
  • 11. CONTRAINDICATIONS & PRECAUTIONS• In hypersensitive animals, Animals with renal diseases, Neonatal & Geriatrics - dose rate reduced & treatment interval increased.• Not recommended in pregnants – adverse effect on foetus
  • 12. TREATMENT• Infusion of neurotropic factor , neurotropin 3 (NT-3) in membraneous labrynth• Dialysis• Administration of carbenicillin or ticarcillin (12- 20g/day) to complex with aminoglycosides• Ca salts or neostigmine given I/v, to treat neuromuscular blockage• Avoiding concurrent use of nephrotoxic drugs